Qubigen CEO Dr. Jonathan Hall to Speak at AusBiotech International Conference 2025
- David Brooks
- Oct 10
- 2 min read
Updated: Oct 13
Qubigen is proud to announce that its CEO, Dr. Jonathan Hall, will be speaking at the AusBiotech International Conference 2025. This is Australia’s premier life sciences event, bringing together industry leaders, innovators, entrepreneurs and researchers in biotechnology, pharmaceuticals, and medical innovation from across the globe.
Date | Thursday, October 23, 2025 |
Time | 2.30 PM |
Location | Pioneer Room, Melbourne Convention & Exhibition Centre, 1 Convention Centre Pl, South Wharf VIC 3006. |
Session | 8A Pharma 4.0: Computational Approaches to Enhancing Early-Stage Drug Discovery and Development, Transformation Through Integrated AI Expertise |
Dr. Jonathan Hall will speak as part of a panel of experts in computational AI drug discovery; Dr. Milica Ng (CSL), Dr. Michelle Booden (Merck Research Labs) and A/Prof. Michael Menden (University of Melbourne). The session will provide insights on integrating AI expertise into effective drug design programs, accelerating timelines, lowering costs, and increasing success. Realizing its full potential, however, depends on effective collaboration between computational scientists and traditional drug development experts, each with distinct skill sets, scientific languages. and backgrounds. The key challenge lies in embedding AI into existing drug discovery and development workflows.
Dr. Hall will explore how privacy-preserving Federated AI can accelerate innovation in drug design across institutions and sectors. His talk will focus on Qubigen’s pioneering work in secure, distributed machine learning frameworks that enable research organizations and pharma companies to collaborate, creating powerful models without sharing sensitive data. Qubigen’s fast, cost-effective, adjustable AI Engine and curated federated database can be fine-tuned to select the right data suitable for novel, optimized lead candidate generation.
Qubigen is actively seeking collaborators, clients, and partnerships with organizations interested in leveraging Federated AI for drug design. Qubigen invites conference attendees to connect with Dr. Hall during the event to discuss opportunities.
Qubigen: accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
